EUVIMEDEUVIMED entdecken
Crossref

Sex Differences in Cardiotoxicity of Anaplastic Lymphoma Kinase Inhibitors: An Analysis of the FDA Adverse Event Reporting System

Hiroki Asano, Yoshihiro Noguchi, Rikuto Masuda, Makiko Go, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura

Oncology · 2025

DOI: 10.1159/000548896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2025. Verfasst von Hiroki Asano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan, hiro6imp@yahoo.co.jp. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Anaplastic Lymphoma Kinase, Cardiotoxicity, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely characterized, particularly with respect to sex differences. Given the high prevalence of cardiovascular disease in patients with NSCLC, understanding potential sex-specific risks is critical.

Methods

We conducted a pharmacovigilance analysis using the US FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q3 2021) to examine cardiotoxicity signals associated with five ALK-TKIs (alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib). Adverse events were classified using the MedDRA hierarchy, focusing on cardiac disorders. Disproportionality analysis was performed via the Bayesian Confidence Propagation Neural Network (BCPNN) method, calculating Information Component (IC) scores. Sex differences were assessed by computing the IC delta and its 95% confidence interval.

Results

Cardiotoxicity signals, particularly heart failure and pericardial disorders, were detected for alectinib, ceritinib, crizotinib, and lorlatinib but not brigatinib. Notably, significant female-specific signals emerged for left ventricular failure with alectinib; pericardial disorders with ceritinib and crizotinib; and heart failure not elsewhere classified (the MedDRA category used for heart failure cases that do not fall into specific classifications) with crizotinib.

Conclusion

This is the first study to identify sex differences in ALK-TKI-associated cardiotoxicity, highlighting a consistent female predominance in reported adverse events. In particular, considering its widespread use and the clinical importance of left ventricular failure, the pronounced disproportionality signal of cardiotoxicity in females associated with alectinib is thought to have substantial clinical impact. These results underscore the need for heightened clinical vigilance and further research into sex-specific risk stratification and preventive strategies for cardiotoxicity in patients receiving ALK-TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsAnaplastic Lymphoma KinaseCardiotoxicityLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansFemaleMaleUnited StatesAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationSex FactorsPyrimidinesSulfonesPiperidinesPharmacovigilanceCrizotinibMiddle AgedPyrazolesCarbazolesAgedAminopyridinesLactamsOrganophosphorus Compounds

Stichwörter der Autor:innen

Anaplastic lymphoma kinase tyrosine kinase inhibitorsCardiotoxicityDisproportionality analysisFDA Adverse Event Reporting SystemSex differences

Substanzen

Protein Kinase InhibitorsAnaplastic Lymphoma KinasePyrimidinesceritinibSulfonesPiperidinesCrizotinibPyrazolesalectiniblorlatinib

Autor:innen und Institutionen

  • Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan, hiro6imp@yahoo.co.jp.
  • Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan, noguchiy@gifu-pu.ac.jp.
  • Laboratory of Medical Collaborative Pharmacy, Gifu Pharmaceutical University, Gifu, Japan, noguchiy@gifu-pu.ac.jp.
  • Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.
  • Department of Pharmacy, Ogaki Municipal Hospital, Gifu, Japan.
  • Laboratory of Medical Collaborative Pharmacy, Gifu Pharmaceutical University, Gifu, Japan.

Zitieren

APA

Asano, H., Noguchi, Y., Masuda, R., Go, M., Kimura, M., Usami, E., & Yoshimura, T. (2025). Sex Differences in Cardiotoxicity of Anaplastic Lymphoma Kinase Inhibitors: An Analysis of the FDA Adverse Event Reporting System. Oncology. https://doi.org/10.1159/000548896

Vancouver

Asano H, Noguchi Y, Masuda R, Go M, Kimura M, Usami E, et al. Sex Differences in Cardiotoxicity of Anaplastic Lymphoma Kinase Inhibitors: An Analysis of the FDA Adverse Event Reporting System. Oncology. 2025. doi:10.1159/000548896

BibTeX
@article{Asano2025,
  author = {Asano, Hiroki and Noguchi, Yoshihiro and Masuda, Rikuto and Go, Makiko and Kimura, Michio and Usami, Eiseki and Yoshimura, Tomoaki},
  title = {Sex Differences in Cardiotoxicity of Anaplastic Lymphoma Kinase Inhibitors: An Analysis of the FDA Adverse Event Reporting System},
  journal = {Oncology},
  year = {2025},
  doi = {10.1159/000548896}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche